SORT-OUT V: Similar results of biolimus eluting stent with biodegradable polymer versus sirolimus eluting stent with permanent polymer.

The last results of the SORT OUT V submitted in PCR 2012 showed that biolimus eluting stent with  biodegradable polymer was not able to reach the non-inferiority versus sirolimus eluting stent with permanent polymer.

Results to 3 years are now available, and  the new device reached the non-inferiority with a MACE rate of 11.2% for biodegradable polymer stent versus 10.1% for the permanent polymer (p = 0.41) are now displayed. Stroke rates were also similar (3.7% versus 3.5%, P = 0.73), stent thrombosis (1.4% versus 1%, p = 0.45) and target vessel revascularization (6.6% versus 7%, P = 0.69). 

Conclusion 

No significant differences between the biodegradable polymer stent the stent permanently versus the permanent polymer stent at 3 years were observed. 

5_e_christiansen
E. Christiansen
2014-05-22

Title: DESSOLVE II trial results: 2-year follow-up of a crystalline sirolimus-eluting stent with rapid bioabsorbable polymer

More articles by this author

IBERIAN: appendage occlusion registry

The aim of this study was to observe the rate of thromboembolic and hemorrhagic events in a period of 2 years in 167 patients...

COMPARE II: biolimus eluting stent with biodegradable polymer versus everolimus at 3 years.

This study randomized 2:1 - 2707 patients to biolimus eluting stent with biodegradable polymer versus everolimus eluting stent with permanent polymer. At one year,...

Bivalirudin superior than heparin beyond the use or not of Glycoprotein inhibitors

Bivalirudin benefits in bleeding events versus heparin plus glycoprotein IIbIIIa inhibitors is clear even though  this benefit has not been fully studied at the...

Meta-analysis confirms the reduction in ischemic events with 2nd generation DES versus BMS

This paper included 5 studies that randomized patients to conventional stent versus chromium cobalt everolimus eluting stent; at 2 years, a significantly lower risk...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....